Skip to main content

Table 1 Patient demographics

From: Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

  Characteristic Overall
  n %
Number 24  
Age   
Range 35-70
Median 60
Sex   
Male 17 71%
Female 7 39%
Stage   
II 4 16.5%
III 16 67%
IV 4 16.5%
Karnofsky performance status
90% 7 29%
100% 16 67%
Unknown 1 4%
Prior therapy   
None 17 71%
Temozolomide alone 1 4.1%
Radiation alone 2 8.3%
RSA ablation 1 4.1%
Interferon 1 4.1%
Temozolomide + 1 4.1%
Radiation
Temozolomide + 1 4.1%
Isolated limb infusion